162 related articles for article (PubMed ID: 38527797)
1. The role of leukocytes in myeloproliferative neoplasm thromboinflammation.
Liu Y; Wang Y; Huang G; Wu S; Liu X; Chen S; Luo P; Liu C; Zuo X
J Leukoc Biol; 2024 May; 115(6):1020-1028. PubMed ID: 38527797
[TBL] [Abstract][Full Text] [Related]
2. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
3. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
Hasselbalch HC; Elvers M; Schafer AI
Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
[TBL] [Abstract][Full Text] [Related]
4. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
Bhuria V; Baldauf CK; Schraven B; Fischer T
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
[TBL] [Abstract][Full Text] [Related]
5. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
Reeves BN; Beckman JD
Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
[TBL] [Abstract][Full Text] [Related]
6. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.
Ferrer-Marín F; Cuenca-Zamora EJ; Guijarro-Carrillo PJ; Teruel-Montoya R
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498945
[TBL] [Abstract][Full Text] [Related]
7. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.
Ball S; Thein KZ; Maiti A; Nugent K
J Thromb Thrombolysis; 2018 May; 45(4):516-528. PubMed ID: 29404876
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte adhesion and thrombosis.
Afshar-Kharghan V; Thiagarajan P
Curr Opin Hematol; 2006 Jan; 13(1):34-9. PubMed ID: 16319685
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis in myeloproliferative neoplasms.
Falanga A; Marchetti M
Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
[TBL] [Abstract][Full Text] [Related]
11. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
12. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic disease in the myeloproliferative neoplasms.
Falanga A; Marchetti M
Hematology Am Soc Hematol Educ Program; 2012; 2012():571-81. PubMed ID: 23233637
[TBL] [Abstract][Full Text] [Related]
14. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms.
Schafer AI
Hematol Oncol Clin North Am; 2021 Apr; 35(2):305-324. PubMed ID: 33641871
[TBL] [Abstract][Full Text] [Related]
16. Thromboinflammation in Therapeutic Medicine.
Ekdahl KN; Teramura Y; Asif S; Jonsson N; Magnusson PU; Nilsson B
Adv Exp Med Biol; 2015; 865():3-17. PubMed ID: 26306440
[TBL] [Abstract][Full Text] [Related]
17. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
18. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
19. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
Marchetti M; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
Mihaila RG
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Mar; 161(1):50-53. PubMed ID: 28145534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]